The Resurgence of Insulin Sensitizers and the Rise of CGMs
Insulin sensitizers, such as metformin and thiazolidinediones (TZDs), are being recognized for their potential in treating conditions beyond diabetes. Metformin, a commonly used drug for type 2 diabetes, has shown benefits in improving cardiovascular and cerebrovascular risk factors in patients with type 1 diabetes. TZDs, like pioglitazone, enhance insulin activity and can be combined with insulin therapy to improve glycemic control and reduce insulin dose requirements. These drugs also have the potential to treat polycystic ovary syndrome and infertility. As research continues, insulin-sensitizing drugs are regaining attention as a promising approach to various conditions related to insulin resistance.